CoChat

The 'forgotten' bile acid sequestrants: is now a good time to remember?

Bays, Harold E, Goldberg, Ronald B · 2007 · American Journal of Therapeutics

The DOI matches its Crossref record; 131 of the 134 references it cites were found in a registry or an index.

Abstract

Over 30 years ago, bile acid sequestrants (BAS) were among the first drugs approved to lower cholesterol levels. For over 10 years, BAS have been known to reduce glucose levels. Most importantly, BAS have been shown in outcomes studies to reduce cardiovascular events. Because they are true nonsystemic agents, BAS are generally safe and not associated with serious systemic adverse experiences. Despite their proven atherosclerotic coronary heart disease (CHD) benefits, and irrespective of their favorable effects on major CHD risk factors (hypercholesterolemia and hyperglycemia), BAS are not among the more frequently used drug treatments for hypercholesterolemia, even in patients with type 2 diabetes mellitus. Recent "high-profile" findings of investigational and approved lipid-altering and antidiabetes drug therapies illustrate that drug-induced improvements in lipid and glucose levels do not always reduce CHD risk. It may therefore be time to reconsider the clinical use of BAS. This review focuses on the recent lessons learned, and the potential mechanisms involved in efficacy and safety issues raised with torcetrapib and rosiglitazone with analogies related to the use of BAS therapy. Known and proposed mechanisms of how BAS may improve lipid and glucose levels are discussed, which are effects that may help explain how BAS reduce CHD risk. Improved tolerability of newer BAS (eg, colesevelam hydrochloride) and a "new" appreciation of the historic benefits of these "old" therapeutic agents may lead to an increased treatment role for these drugs, particularly in hypercholesterolemic patients with type 2 diabetes mellitus.

Overview

Integrity signals

Registry

Crossref · 10.1097/mjt.0b013e31815a69fc

Cites

131 of 131 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 131 references

Research works printed but not linked: 4

  1. 1998, 2 diabetes UKPDS 33. UK Prospective Diabetes Study UKPDS Group., Lancet, 352, 837
  2. 1994, 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study 4S., Lancet, 344, 1383
  3. Zhang, 2006, Activation of the nuclear receptor FXR improves hyperglycemia and hyperlipidemia in diabetic mice., Proc Natl Acad Sci USA, 103, 1006, 10.1073/pnas.0506982103 · DOI · Paper page
  4. Bays, 2006, Adiposopathy is a more rational treatment target for metabolic disease than obesity alone., Curr Atheroscler Rep, 8, 144, 10.1007/s11883-006-0052-6 · DOI

Cited by

See all 83

Metadata

Authors
Bays, H. E., & Goldberg, R. B.
Affiliations
  • Louisville Metabolic and Atherosclerosis Research Center (US)
  • University of Miami (US)
Corresponding author
Bays, Harold E
Venue
American Journal of Therapeutics
Published
2007-11
Volume
14
Issue
6
Pages
567-580
ISSN
1075-2765 (ISSN-L)
OpenAlex
W2037964248
Cited by
83
References
134
Citations by year
2025: 1 · 2023: 4 · 2022: 4 · 2021: 1 · 2017: 1 · 2016: 4 · 2015: 7 · 2014: 7 · 2013: 5 · 2012: 7
FWCI
2.04
Type
journal article
Language
en
Open access
closed
Locations
  • American Journal of Therapeutics (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Cholesterol and Lipid Metabolism
Keywords
bile acid sequestrants, hypercholesterolemia, type 2 diabetes, coronary heart disease risk, blood glucose reduction, cholesterol lowering, torcetrapib, rosiglitazone, colesevelam, drug safety, lipid-lowering therapy, glucose-lowering therapy
MeSH terms
Liver X Receptors, Anticholesteremic Agents, Bile Acids and Salts, Blood Glucose, Cholestyramine Resin, Clinical Trials as Topic, Colestipol, Diabetes Mellitus, Type 2, DNA-Binding Proteins, Humans, Lipids, Receptors, Cytoplasmic and Nuclear, Dyslipidemias, Orphan Nuclear Receptors

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: The 'forgotten' bile acid sequestrants: is now a good time to remember? https://app.cochat.ai/papers/10.1097/mjt.0b013e31815a69fc
The paper
Bays, H. E., & Goldberg, R. B. (2007). The 'forgotten' bile acid sequestrants: is now a good time to remember? American Journal of Therapeutics. https://doi.org/10.1097/mjt.0b013e31815a69fc

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.